Recursion Pharmaceuticals (RXRX): Assessing Valuation with AI Strategy in Focus Ahead of Key CEO Presentation [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
The focus is on how the company's AI strategy and outlook could shape its future direction. See our latest analysis for Recursion Pharmaceuticals. Recursion's share price has seen big swings lately, including a strong rally earlier this week as buzz grew around upcoming AI-focused announcements following recent partnerships and pipeline refocusing. However, its 1-year total shareholder return of -19.6% and significant drop year-to-date show that longer-term sentiment remains cautious even as short-term momentum builds. If Recursion's AI ambitions caught your attention, now is a perfect opportunity to discover other innovators with See the full list for free. That leaves investors weighing a key question. With recent volatility and anticipation pushing prices higher, is Recursion undervalued given its AI-driven potential, or has the market already accounted for future growth opportunities? Most Popular Narrative: 17.7% Undervalued Recursion Pharmaceuticals closed at $5.32,
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Lightning Round: Recursion Pharmaceuticals and NuScale Power [CNBC]CNBC
- Cramer's Lightning Round: Recursion Pharmaceuticals ‘has been horrendous' [CNBC]CNBC
- Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025GlobeNewswire
- Is Recursion Pharmaceuticals a Meme Stock? [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 4
- 12/4/25 - Form 144
- RXRX's page on the SEC website